CD200 and ovarian cancer: These findings suggest that reduced SUMOylation levels may regulate the expression of PI3, AUP1, CD200 and GNAS in ovarian cancer cells, thereby influencing cancer cell survival, proliferation, metastasis and chemoresistance by modulating cell functions and metabolism.